⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
MRK News
Merck & Co., Inc.
INVESTIGATION ALERT: Levi & Korsinsky, LLP Announces Investigation of Merck Sharp & Dohme LLC Data Breach
accessnewswire.com
MRK
Merck Manuals Answers Common Questions About Age-Related Macular Degeneration
prnewswire.com
MRK
Neuphoria Therapeutics Inc. Sends Letter to Stockholders
globenewswire.com
NEUP
MRK
EMD Serono Takes Patient-Directed Approach to Bring Innovation to the Treatment of Rare Neuromuscular Disorder, Generalized Myasthenia Gravis
businesswire.com
MRK
Kelun-Biotech Announces Phase III Trial of Sac-TMT in Combination with KEYTRUDA® (pembrolizumab) as First-Line Treatment for PD-L1-Positive NSCLC Met Primary Endpoint USA - English APAC - English
prnewswire.com
MRK
Merck Data to be Presented at ASH 2025 Annual Meeting Showcase Continued Advancements in Hematology Pipeline and Novel Therapeutic Approaches
businesswire.com
MRK
Cell Therapy Market Size Set to More Than Double by 2030 -- North America Leads, While Asia-Pacific Emerges as the Fastest-Growing Region, Says Mordor Intelligence
prnewswire.com
NVS
BMY
JNJ
SRPT
GILD
TMO
DHR
SART
MRK
BDX
Merck Recommends Rejection of Tutanota’s “Mini-Tender” Offer
businesswire.com
MRK
FDA Approves KEYTRUDA ® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev ® (enfortumab vedotin-ejfv), as Perioperative Treatment for Adults with Cisplatin-Ineligible Muscle-Invasive Bladder Cancer
businesswire.com
MRK
Levi & Korsinsky, LLP Investigates Merck Sharp & Dohme LLC Data Breach
accessnewswire.com
MRK